Real-world effectiveness of central dialysis fluid delivery system (CDDS) in maintenance hemodialysis: a retrospective multicenter study.
Central dialysis fluid delivery raised serum albumin in hemodialysis patients versus single-patient systems
Real-world effectiveness of central dialysis fluid delivery system (CDDS) in maintenance hemodialysis: a retrospective multicenter study.
This study aimed to compare the real-world effectiveness of a central dialysis fluid delivery system (CDDS) with single-patient dialysis delivery systems (single-patient dialysis delivery systems) in patients undergoing maintenance hemodialysis (maintenance hemodialysis), focusing on inflammation markers, nutritional status, and dialysis adequacy.
We conducted a retrospective cohort analysis of 368 maintenance hemodialysis patients from three hemodialysis centers in Shanghai, China, between January 2020 and June 2023 was analyzed (CDDS, n = 253; single-patient dialysis delivery systems, n = 115).
Generalized linear mixed-effects models were used to evaluate longitudinal associations between dialysate delivery systems and clinical outcomes.
Subgroup analysis indicated that CDDS was particularly effective in improving albumin levels among patients aged < 70 years, those with diabetes, or those with elevated CRP levels.
In patients aged ≥ 70, CDDS was associated with better anemia control and enhanced dialysis adequacy.
In conclusion, CDDS use was associated with improved nutritional and hematologic indicators in this real-world cohort, while differences in inflammatory markers and dialysis adequacy were not statistically significant after multivariable adjustment.